Samsung Biologics eyes global market with acquisition of Samsung Bioepis: CEO
By Kim Han-joo
SEOUl, March 29 (Yonhap) -- Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, aims to expand its presence in the global market through full ownership of Samsung Bioepis, its chief executive said Tuesday.
Samsung Biologics is the leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of biopharmaceutical products for major pharmaceutical firms from both home and abroad.
In an aim to expand its business sector, Samsung Biologics reached a deal with Biogen Inc. earlier this year to buy the U.S. drugmaker's entire stake in Samsung Bioepis for US$2.3 billion.
"Through the takeover of Samsung Bioepis' shares, we aim to develop into a biopharmaceutical firm that comprehensively has three pillars -- CDMO, biosimilars and new drug development," CEO John Rim said during a shareholders' meeting.
Rim also said the transaction is expected to boost its earnings growth on a consolidated basis by fully capitalizing on Samsung Bioepis' growth outlook.
For 2021, Samsung Biologics reported a net profit of 393.6 billion won (US$322.5 million), up 63.3 percent from a year earlier, on the back of the stellar performance of its flagship drugs.
"The company reported sales and operating income (for 2021) that jumped 35 percent and 84 percent, respectively, despite being in the midst of the COVID-19 pandemic, by securing more deals and increasing operation of three plants," the chief said.
Samsung Biologics currently operates three plants in Songdo, west of Seoul, and is building its fourth plant, which is set to be partially operational from October starting with a bioreactor capacity of 60,000 liters.
With the fourth plant's completion, the company is expected to secure a combined bioreactor capacity of 620,000 liters by 2023, making it the largest contract manufacturing organization facility at a single location in the world.
khj@yna.co.kr
(END)
-
BTS' RM to prerelease a track of 2nd solo album
-
'Queen of Tears' weaves rich tapestry of Korean contemporary art
-
Indonesia coach left with mixed feelings after eliminating native S. Korea in Olympic football qualifiers
-
N. Korea says Kim guided simulated nuclear counterattack drills for 1st time
-
N. Korea calls envisioned U.S. aid to Ukraine 'hallucinogen'
-
'Queen of Tears' weaves rich tapestry of Korean contemporary art
-
BTS' RM to prerelease a track of 2nd solo album
-
N. Korea says Kim guided simulated nuclear counterattack drills for 1st time
-
Looming weekly closure of major hospitals feared to worsen medical service crisis
-
N. Korea calls envisioned U.S. aid to Ukraine 'hallucinogen'
-
N. Korea installs mines on inter-Korean road within DMZ
-
N. Korea decries U.S. shipment of long-range tactical missiles to Ukraine as 'mean' policy
-
FM's visit to China under discussion
-
Yoon, opposition leader set to hold first-ever meeting Monday
-
(LEAD) N. Korea installs mines on inter-Korean road within DMZ